CJC-1295 (without DAC) vs Exemestane
Well Studied vs FDA Approved
synergistic Mechanism-based · 60% Exemestane helps manage estrogen conversion from CJC-1295 (without DAC). This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 (without DAC) Exemestane
Weight 3,367.97 Da 296.40 Da
Half-life 30 minutes - 2 hours ~24 hours
Chain 30 amino acids —
Type GHRH analog Steroidal aromatase inhibitor (irreversible, suicide inhibitor)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Exemestane
12.5mg EOD or 25mg E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Research Evidence
CJC-1295 (without DAC) Exemestane
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.